Pheophorbide a, a moiety of chlorophyll a, induces apoptosis in human lymphoid leukemia molt 4B cells.

Hibasami, Hiroshige; Kyohkon, M; Ohwaki, S; Katsuzaki, Hirotaka; Imai, Kunio; Nakagawa, Masako; Ishi, Y; Komiya, Takashi

doi:10.3892/ijmm.6.3.277

Cited by 18 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Development of drug resistance is multi-factorial, the overexpression of P-glycoprotein, which is a plasma membrane protein causing drug resistance, is common in the MDR cells. 7 It was shown that the cytotoxicity of Pa remained unchanged on R-HepG2 cells when P-glycoprotein inhibitor was applied (Fig. 2B).…”

Section: Discussionmentioning

confidence: 86%

“…Previous studies illustrated that Pa significantly inhibited the growth of human liver cancer 6 skin cancer and leukemia in vitro. 7,8 In this study, the effects of Pa were examined on two human hepatoma cell lines, HepG2 as well as R-HepG2, which are characterized by over-expression of P-glycoprotein and resistance against multiple anti-tumor drugs. 9 Our results revealed that Pa could circumvent drug resistance, inhibit the expression of P-glycoprotein, and induce cell cycle arrest in R-HepG2 cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pheophorbide a, an active component in scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2

Tang

Chan²,

Zhang³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

Scutellaria barbata, a Traditional Chinese Medicine native in southern China, has been widely used for treating liver diseases. In this study, the anti-proliferative effect of Pheophorbide a (Pa), an active component from S. barbata, was examined on a multi-drug resistant (MDR) human hepatoma cell line R-HepG2. Our study showed that Pa could significantly inhibit the growth of R-HepG2 cells with an IC 50 value at 25.0mM after 48 hours treatment. When compared with the parental HepG2 cells, Pa showed weak resistance to R-HepG2. Efflux of Pa out of R-HepG2 cells was not observed as its cellular uptake level showed no significant difference comparing with HepG2 cells. Interestingly, significant reduction of P-glycoprotein expression on Pa-treated R-HepG2 cells was found at both transcriptional and translational levels, leading to reduction of P-glycoprotein activity. In addition, mechanistic study elucidated that Pa induced cell cycle arrest at G 2 /M phase and inhibited the expressions of G 2 /M phase cell cycle regulatory proteins, cyclin-A1 and cdc2 in a dose-dependent manner.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Pheophorbide a, an active component in scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2

Tang

Chan²,

Zhang³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…31 Pheophorbide a, a chlorophyll derivative, was shown to have antimutagenic activity and to inhibit tumor cell growth. 32 It may also have the ability to induce apoptosis 33 and antitumor-promoting activity. 34 Folate deficiency has been associated with colorectal, 35 breast 36 and head-andneck 37 cancer, which may involve DNA damage, aberrant methylation and abnormal apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma

Korenaga

Naito

Okayama

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Breast cancer resistance protein (BCRP), the second member of the ATP-binding cassette membrane transporter family, has a single nucleotide polymorphism, C421A (resulting in Q141K), that is of functional importance. Our aim was to explore the relationship between this polymorphism of the BCRP gene and the risk of renal cell carcinoma (RCC) development. For a case-control study, DNA samples from 200 nonpapillary RCC patients and 200 healthy control subjects were analyzed using the TaqMan technique. The genotypic frequencies of the BCRP C421A polymorphism were compared between RCC patients and control subjects. The frequency of the C/C genotype was significantly higher in RCC patients than in control subjects (age-and gender-adjusted OR 5 1.96, 95% CI 1.32-2.93). No associations were observed between the BCRP C421A polymorphism and clinicopathologic or epidemiologic factors, including age, gender, tumor grade, stage, cigarette smoking, family history of cancer and body mass index. Carriers with the C/C genotype of the BCRP C421A polymorphism are at risk of developing nonpapillary RCC. These data suggest that BCRP is a candidate RCC susceptibility gene. ' 2005 Wiley-Liss, Inc.Key words: breast cancer resistance protein; single nucleotide polymorphism; renal cell carcinoma RCC is the most common malignancy of human adult kidneys and accounts for 2-3% of all cancers. Approximately 80% of all RCCs belong to the clear cell subtype, originating from the proximal epithelia.1 The prevalence of RCC is increasing, 2,3 probably for the following reasons: (i) an improved detection rate arising from the widespread use of noninvasive imaging procedures, such as ultrasonography, CT and MRI; (ii) prolongation of the life span in developed countries; and (iii) increases in environmental risk factors, especially exogenous carcinogens derived from various foods and industrial processes. Regarding the metabolism of such xenobiotics, genetically polymorphic enzymes such as cytochrome P-450, glutathione S-transferase and N-acetyltransferase have been reported to modulate renal cancer risk.4-6 Detection of high-risk groups based on the knowledge of cancer-susceptibility genes is clearly important for further improvement in the early diagnosis and prevention of RCC.Accumulating evidence has revealed that transporter molecules involved in the distribution, delivery and penetration of environmental agents into cellular and subcellular compartments may also play roles in the risk of renal cancer development.7,8 P-gp (MDR1/ABCB1), MRP2 (ABCC2) and BCRP (ABCG2) are members of the ABC transporter family, which function in the uptake, binding, transport and distribution of xenobiotics. P-gp is a plasma membrane transporter encoded by MDR1. Studies have shown that these proteins are expressed not only in cancer cells for effluxing multi-anticancer agents but also in the apical membrane of normal enterocytes, where they presumably act as ''gatekeepers'', controlling the oral availability of many substances. 9This hypothesis could be applicable t...

show abstract

“…PDT uses porphyrin derivatives to produce singlet oxygen and ROS through visible light irradiation, leading to apoptotic and necrotic tumor cell death (Hajri et al, 1999;Hibasami et al, 2000;Oleinick et al, 2002;Tang et al, 2006). Pba mediates mitochondrial membrane perturbation and consequent cytochrome c release, resulting in apoptotic cell death (Tang et al, 2009).…”

Section: Role Of C-met/bcrp Signaling In Cancer Resistancementioning

confidence: 99%

The c-MET/PI3K Signaling Is Associated with Cancer Resistance to Doxorubicin and Photodynamic Therapy by Elevating BCRP/ABCG2 Expression

2014

View full text Add to dashboard Cite

Pheophorbide a, a moiety of chlorophyll a, induces apoptosis in human lymphoid leukemia molt 4B cells.

Cited by 18 publications

References 0 publications

Pheophorbide a, an active component in scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2

Pheophorbide a, an active component in scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2

Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma

The c-MET/PI3K Signaling Is Associated with Cancer Resistance to Doxorubicin and Photodynamic Therapy by Elevating BCRP/ABCG2 Expression

Contact Info

Product

Resources

About